RenovoRx raises $7m for drug-device pancreatic cancer therapy

RenovoRx said today that it closed a $7 million tranche in a $10 million round to fund the development of its drug-device combination product designed to deliver chemotherapy directly to tumors in patients with locally advanced pancreatic cancer. The company’s round was led by Boston Scientific (NYSE:BSX) and joined by btov Partners, Astia Angels, Golden Seeds and others. Get the full story at our sister site, Drug Delivery Business News. The post RenovoRx raises $7m for drug-device pancreatic cancer therapy appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Food & Drug Administration (FDA) Funding Roundup Oncology Pharmaceuticals Regulatory/Compliance Vascular RenovoRx Source Type: news

Related Links:

Conclusion: The co-delivery of Gem and miR-21i using Au DENPs can be significantly promoted by UTMD technology, hence providing a promising strategy for effective pancreatic cancer treatments.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Introduction: Hyperglycaemia is a significant cause of morbidity in cancer patients accounting for up to 5% of emergency oncology admissions (1). The incidence of hyperglycaemia in non-diabetic patients receiving anti-cancer therapy has been shown to be as high as 11.6% (2). One significant factor is the high doses of steroids administered either as part of the systemic anti-cancer treatment to control nausea and vomiting, or to palliate other cancer-related symptoms such as pain or anorexia. Patients with gastro-intestinal (GI) malignancies, in particular, often receive high doses of steroids as part of their chemotherapy...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
The signaling pathway driven by p38 and MAPKAPK2 alias MK2 is activated as part of stress responses, and these kinases represent attractive drug targets for cancer therapy. However, seemingly conflicting results were obtained when assessing the role of MK2 in chemotherapy. MK2 inhibitors were reported to either enhance or diminish the chemosensitivity of cancer cells. Here we show that this strongly depends on the particular chemotherapeutic drug. Two different MK2 inhibitors increased the proliferating fraction of pancreatic cancer-derived cells upon treatment with gemcitabine, whereas no consistent protection against cisplatin was observed.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Journal of Cellular Biochemistry, EarlyView.
Source: Journal of Cellular Biochemistry - Category: Biochemistry Authors: Source Type: research
Dr. Antonio Giordano believes his team has cleared the path to the next breakthrough in the treatment of malignant pleural mesothelioma. The advancement involves a new use for an old drug, pyrvinium pamoate, which doctors have successfully used for more than 50 years to treat infections of pinworm parasite. “This drug that no one expected to be involved with mesothelioma is potentially a new weapon against this aggressive type of tumor,” Giordano told Asbestos.com. “Our findings are exciting, very exciting. This one can move forward.” Giordano is the founder and director of the Sbarro Health Researc...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSIONS: Combination chemotherapy has recently overtaken the long-standing gemcitabine as the standard of care. FOLFIRINOX and gemcitabine plus nab-paclitaxel are highly efficacious, but our analysis shows that other combination regimens also offer a benefit. Selection of the most appropriate chemotherapy for individual patients still remains difficult, with clinicopathological stratification remaining elusive. Biomarker development is essential to help rationalise treatment selection for patients. PMID: 29557103 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
ConclusionHigh‐throughput drug screening on organoids, combined with next‐generation sequencing, proteomic analysis and other state‐of‐the‐art molecular diagnostic methods, can shape cancer treatment to become more effective with fewer side‐effects.
Source: British Journal of Surgery - Category: Surgery Authors: Tags: Review Source Type: research
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. It has an excessive desmoplastic stroma that can limit the intratumoral delivery of chemotherapy drugs, and protect tumor cells against radiotherapy. Therefore, both stromal and tumor compartments need to be addressed in order to effectively treat PDAC. We hereby co-deliver a sonic hedgehog inhibitor, cyclopamine (CPA), and a cytotoxic chemotherapy drug paclitaxel (PTX) with a polymeric micelle formulation (M-CPA/PTX). CPA can deplete the stroma-producing cancer-associated fibroblasts (CAFs), while PTX can inhibit tumor proliferation...
Source: Biomaterials - Category: Materials Science Authors: Tags: Biomaterials Source Type: research
In this study, the expression of the neuropilin-1 receptor in both pancreatic and prostate cancer stem cells was identified and targeted with a stimuli-responsive, polymeric nanocarrier to deliver a stemness inhibitor (napabucasin) to cancer stem cells. Reduction-sensitive amphiphilic block copolymers PEG1900-S-S-PLA6000 and the N3-PEG1900-PLA6000 were synthesized. The tumor penetrating iRGD peptide-hexynoic acid conjugate was linked to the N3-PEG1900-PLA6000 polymer via a Cu2+ catalyzed “Click” reaction. Subsequently, this peptide-polymer conjugate was incorporated into polymersomes for tumor targeting and tis...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Funding | Pancreas | Pancreatic Cancer